Virax Biolabs Group Limited Ordinary Shares (VRAX) is a publicly traded Healthcare sector company. As of May 21, 2026, VRAX trades at $0.32 with a market cap of $1.74M and a P/E ratio of 0.00. VRAX moved +2.30% today. Year to date, VRAX is -16.86%; over the trailing twelve months it is -70.87%. Its 52-week range spans $0.10 to $3.62. Rallies surfaces VRAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own VRAX include Renaissance Technologies. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Virax Biolabs Group Limited Ordinary Shares.
| Metric | Value |
|---|---|
| Price | $0.32 |
| Market Cap | $1.74M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.62 |
| 52-Week Low | $0.10 |
| Volume | 859.40K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
VRAX analyst coverage data. Average price target: $0.00.